Biofidelity is developing a novel molecular diagnostic technology for the detection of smallamounts of circulating tumour DNA in a blood sample.

With a limit of detection 10-50x lower than the current FDA-approved methods, the Company can identify known mutations whose presence or absence can guide clinical decisions. Sensitive liquid biopsy techniques hold great promise as companion diagnostics for the accurate diagnosis and treatment of cancers, allowing regular, noninvasive monitoring of patients.

Visit website